|Bid||16.50 x 4000|
|Ask||19.72 x 2200|
|Day's range||19.47 - 20.25|
|52-week range||11.98 - 25.35|
|Beta (5Y monthly)||1.49|
|PE ratio (TTM)||N/A|
|Earnings date||23 Jul 2020 - 27 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||19.09|
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes plc (NASDAQ:ALKS) just released its first-quarter report and things are looking bullish. Revenues and losses...
Potential Alkermes plc (NASDAQ:ALKS) shareholders may wish to note that the Independent Director, Nancy Wysenski...
Alkermes (ALKS) delivered earnings and revenue surprises of 25.76% and 1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The FDA accepts for review Alkermes' (ALKS) NDA for ALKS 3831 for the treatment of schizophrenia and bipolar I disorder and has set an action date of Nov 15, 2020.
Seattle Genetics (SGEN) submits an NDA to the FDA for tucatinib in combination with Herceptin and Xeloda seeking approval to treat locally advanced/metastatic HER2-positive breast cancer.
Alkermes (ALKS) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.